Ventus Therapeutics announced the successful completion of the phase 1 clinical trial for VENT-03 with plans to initiate a ...
With a positive readout for metabolic dysfunction-associated steatohepatitis (MASH) now in the bag, Novo Nordisk is gearing ...
Bagsværd, Denmark Tuesday, November 5, 2024, 10:00 Hrs [IST] ...
Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning.
Results from OVATION 2 Study of IMNN-001 to be highlighted in late-breaking acceptanceCompany also announces FDA End-of-Phase 2 in-person meeting ...
However, a phase 2 trial in the setting ran into challenges ... Editor's note: This story was updated at 10 am on Oct. 3 to include comments from Takeda.
About TROPION-Lung10 TROPION-Lung10 is a global, multicenter, open-label, three-arm phase 3 trial where patients will be randomized in a 2:1:2 ratio to evaluate the efficacy and safety of ...
MSD and Moderna have kicked off another phase 3 trial of their personalised cancer ... high-risk stage 2b to 4 melanoma. The new phase 2 trial is another endorsement of the potential of V940 ...
Stockhead on MSN5d
ASX Quarterly Health Wrap: Action for Dimerix Phase 3 kidney trialIt’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with updates.
The 321-subject trial is comparing the anti-CD40L antibody ... Other candidates include anti-BDCA2 antibody litifilimab in phase 3 for SLE and phase 2 for cutaneous lupus erythematosus (CLE ...
About TROPION-Lung10 TROPION-Lung10 is a global, multicenter, open-label, three-arm phase 3 trial where patients will be randomized in a 2:1:2 ratio to evaluate the efficacy and safety of datopotamab ...
Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback